To resume, anti-angiogenic drugs increase immune-cell infiltration by inducing vessel normalization and can enable more effector cells, such as CD8+ T cells or natural killer cells, to become activated upon tumor-cell recognition, while immunotherapies can activate effector immune cells that can also secrete pro-angiogenic factors, promoting vascular remodeling (Figure 1). The gene discussed is CD8A; the disease is neoplasm.